| Literature DB >> 30419895 |
Feras Darwish Elhajji1, Ghaith M Al-Taani2, Lana Anani3, Sahar Al-Masri4, Haneen Abdalaziz5, Su'ad H Qabba'h6, Abdel Qader Al Bawab7, Michael Scott8, David Farren8, Fiona Gilmore8, Ann Versporten9, Herman Goossens9, Mamoon A Aldeyab10.
Abstract
BACKGROUND: To assess antimicrobial prescribing in a Northern Ireland hospital (Antrim Area Hospital (AAH)) and compare them with those of a hospital in Jordan (Specialty Hospital).Entities:
Keywords: Antimicrobial surveillance; Antimicrobials; Global point prevalence survey; Jordan; Northern Ireland; Point prevalence survey
Mesh:
Substances:
Year: 2018 PMID: 30419895 PMCID: PMC6233602 DOI: 10.1186/s12913-018-3656-y
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
General characteristics of the patients among the study hospitals by medical and surgical admissions
| Medical | Surgical | |||||
|---|---|---|---|---|---|---|
| Characteristics | Antrim Area Hospital ( | Specialty Hospital ( | Antrim Area Hospital ( | Specialty Hospital ( | ||
| Number of treated patients | 165 | 44 | 34 | 41 | ||
| Age of patients (mean) | 70.1 | 47.6 | < 0.001 | 65.0 | 43.5 | < 0.001 |
| Gender | ||||||
| - Male | 83 (50.3) | 29 (65.9) | 0.065 | 12 (35.3) | 28 (68.3) | 0.004 |
| - Female | 82 (49.7) | 15 (34.1) | 22 (64.7) | 13 (31.7) | ||
| Number of prescribed antibioticsa | 239 | 65 | 66 | 56 | ||
| Diagnosis site | ||||||
| - Central nervous system | 4 (2.4) | 3 (6.8) | 0.112 | 0 (0.0) | 0 (0.0) | 0.036 |
| - Eye | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.4) | ||
| - Otolaryngology | 4 (2.4) | 1 (2.3) | 0 (0.0) | 0 (0.0) | ||
| - Respiratory | 78 (47.3) | 15 (34.1) | 2 (5.9) | 3 (7.3) | ||
| - Cardiovascular | 0 (0.0) | 1 (2.3) | 0 (0.0) | 4 (9.8) | ||
| - Gastrointestinal tract | 8 (4.8) | 6 (13.6) | 20 (58.8) | 12 (29.3) | ||
| - Skin, soft tissue, bone, and joint | 14 (8.5) | 6 (13.6) | 3 (8.8) | 14 (34.1) | ||
| - Urinary tract | 21 (12.7) | 6 (13.6) | 4 (11.8) | 4 (9.8) | ||
| - Genito-urinary and obstetrics | 10 (6.1) | 1 (2.3) | 4 (11.8) | 2 (4.9) | ||
| - Undefined site | 23 (13.9) | 5 (11.4) | 1 (2.9) | 0 (0.0) | ||
| - Neonatal | 3 (1.8) | 0 (0.0) | 0 (0.0) | 1 (2.4) | ||
aSome patients were prescribed more than one antibiotic
Antibiotic agents prescribed among the study hospitals (% of prescribed antibiotics)
| Medical | surgical | |||||
|---|---|---|---|---|---|---|
| Antibiotic prescriptions (ATC4) | Antrim Area Hospital ( | Specialty Hospital ( | Antrim Area Hospital ( | Specialty Hospital ( | ||
| Intestinal anti-infectives (antibiotics) (A07AA) | 6 (2.5) | 0 (0.0) | 0.197 | 0 (0.0) | 0 (0.0) | n/a |
| Tetracyclines (J01AA) | 21 (8.8) | 3 (4.6) | 0.269 | 1 (1.5) | 2 (3.6) | 0.465 |
| Penicillins with extended spectrum (J01CA) | 45 (18.8) | 0 (0.0) | < 0.001 | 9 (13.6) | 0 (0.0) | 0.004 |
| Beta-lactamase sensitive penicillins (J01 CE) | 4 (1.7) | 0 (0.0) | 0.294 | 0 (0.0) | 0 (0.0) | n/a |
| Beta-lactamase resistant penicillins (J01CF) | 10 (4.2) | 0 (0.0) | 0.094 | 2 (3.0) | 0 (0.0) | 0.189 |
| Combinations of penicillins, including b-lactamase inhibitors (J01CR) | 45 (18.8) | 8 (12.3) | 0.219 | 13 (19.7) | 4 (7.1) | 0.046 |
| First-generation cephalosporins (J01DB) | 1 (0.4) | 1 (1.5) | 0.322 | 1 (1.5) | 2 (3.6) | 0.465 |
| Second-generation cephalosporins (J01 DC) | 4 (1.7) | 0 (0.0) | 0.294 | 0 (0.0) | 2 (3.6) | 0.122 |
| Third-generation cephalosporins (J01DD) | 5 (2.1) | 17 (26.2) | < 0.001 | 0 (0.0) | 21 (37.5) | < 0.001 |
| Monobactams (J01DF), | 7 (2.9) | 0 (0.0) | 0.163 | 0 (0.0) | 0 (0.0) | n/a |
| Carbapenems (J01DH) | 3 (1.3) | 10 (15.4) | < 0.001 | 1 (1.5) | 12 (21.4) | < 0.001 |
| Trimethoprim and derivatives (J01EA) | 4 (1.7) | 0 (0.0) | 0.294 | 1 (1.5) | 0 (0.0) | 0.355 |
| Combination of trimethoprim/sulfamethoxazole (J01EE) | 6 (2.5) | 0 (0.0) | 0.197 | 0 (0.0) | 0 (0.0) | n/a |
| Macrolides (J01FA) | 23 (9.6) | 3 (4.6) | 0.201 | 0 (0.0) | 0 (0.0) | n/a |
| Aminoglycosides (J01GB) | 11 (4.6) | 6 (9.2) | 0.150 | 13 (19.7) | 1 (1.8) | 0.002 |
| Fluoroquinolones (J01MA) | 3 (1.3) | 12 (18.5) | < 0.001 | 2 (3.0) | 3 (5.4) | 0.518 |
| Glycopeptide antibacterials (J01XA) | 12 (5.0) | 2 (3.1) | 0.507 | 4 (6.1) | 7 (12.5) | 0.216 |
| Steroid antibacterials (J01XC) | 1 (0.4) | 0 (0.0) | 0.601 | 0 (0.0) | 0 (0.0) | n/a |
| Imidazole derivatives (J01XD) | 18 (7.5) | 2 (3.1) | 0.199 | 16 (24.2) | 2 (3.6) | 0.001 |
| Nitrofuran derivatives (J01XE) | 2 (0.8) | 0 (0.0) | 0.459 | 0 (0.0) | 0 (0.0) | n/a |
| Other antibacterials (J01XX) | 0 (0.0) | 1 (1.5) | 0.055 | 1 (1.5) | 0 (0.0) | 0.355 |
| Antimycotics, triazole derivatives (J02 AC) | 2 (0.8) | 0 (0.0) | 0.459 | 0 (0.0) | 0 (0.0) | n/a |
| Antimycotics, other antimycotics for systematic use (J02AX) | 1 (0.4) | 0 (0.0) | 0.601 | 0 (0.0) | 0 (0.0) | n/a |
| Antimycobacterials, antibiotics (J04AB) | 5 (2.1) | 0 (0.0) | n/a | 0 (0.0) | 0 (0.0) | n/a |
| Antivirals, neuraminidase inhibitors (J05AH) | 0 (0.0) | 0 (0.0) | n/a | 0 (0.0) | 0 (0.0) | n/a |
| Antiprotozoals, nitroimidazole derivatives (P01AB) | 5 (2.1) | 1 (0.8) | 0.240 | 2 (3.0) | 0 (0.0) | 0.189 |
n/a: not applicable
Antibiotics prescribed by indication groups among the study hospitals
| medical | surgical | |||||
|---|---|---|---|---|---|---|
| Indication group | Antrim Area Hospital | Specialty Hospital | Antrim Area Hospital | Specialty Hospital | ||
| Community-acquired infection (CAI) | 170 (71.1) | 39 (60.0) | 0.086 | 37 (56.1) | 5 (8.9) | < 0.001 |
| Hospital-acquired infection (HAI) | 43 (18.0) | 0 | n/a | 6 (9.0) | 0 | n/a |
| Surgery prophylaxis | 10 (4.2) | 11 (16.9) | < 0.001 | 21 (31.8) | 50 (89.2) | < 0.001 |
| Medical prophylaxis | 15 (6.3) | 15 (23.1) | < 0.001 | 2 (3.0) | 1 (1.8) | 0.653 |
n/a: not applicable
Targets for quality control among study hospitals
| Medical | Surgical | ||||||
|---|---|---|---|---|---|---|---|
| Group | Antrim Area Hospital (239 antibiotic prescriptions); | Specialty Hospital (65 antibiotic prescriptions); | Antrim Area Hospital (66 antibiotic prescriptions); | Specialty Hospital (56 antibiotic prescriptions); | |||
| Compliance with guidelines (% of prescribed antibiotics) | Compliant | 172/239 (72.0%) | 59/64 (92.2%) | < 0.001 | 54/66 (81.8%) | 51/55 (92.7%) | 0.012 |
| Not compliant | 45/239 (18.8%) | 1/64 (1.6%) | 10/66 (15.2%) | 0 | |||
| Non assessable | 22/239 (9.2%) | 4/64 (6.3%) | 2/66 (3.0%) | 4/55 (7.3%) | |||
| No information | 0 | 1/65 (1.5%) | 0 | 1/56 (1.8%) | |||
| Reason for prescribing antibiotic is documented | 225 (94.1%) | 65 (100%) | 0.046 | 55 (83.3%) | 55 (98.2%) | 0.006 | |
| Stop/review date is documented | 125 (52.3%) | 31 (47.7%) | 0.510 | 32 (48.5%) | 36 (64.3%) | 0.080 | |
| Treatment based on biomarker data (e.g., C reactive protein) | 168 (70.3%) | 35 (53.8%) | 0.001 | 28 (42.4%) | 16 (28.6%) | 0.112 | |